Hypoglycaemic Agents and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease
Key Points Glucose‐lowering therapies differentially influence COPD outcomes beyond glycaemic control. SGLT‐2Is and GLP‐1RAs consistently reduce COPD exacerbations. Metformin shows modest benefit, while DPP‐4Is are largely neutral, and other agents show heterogeneous effects. Insulin is associated with a high risk of COPD exacerbations.
Authors
- Mario Cazzola (ORCID: https://orcid.org/0000-0003-4895-9707)
- Maria Gabriella Matera (ORCID: https://orcid.org/0000-0002-5113-9235)
Institutions
- University of Rome Tor Vergata (IT)
- University of Campania "Luigi Vanvitelli" (IT)
Publication Details
- Journal
- Respirology
- Published
- 2026-07-28
- DOI
- https://doi.org/10.1002/resp.70293
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00